Clinical Trial Update: A Study Evaluating the Safety and Efficacy of Venetoclax (GDC-0199) Plus Bendamustine + Rituximab (BR) in Comparison With BR or Venetoclax Plus Rituximab in Participants With Relapsed and Refractory Follicular Non-Hodgkin's Lymphoma (fNHL) [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating venetoclax with BR versus BR or venetoclax with rituximab in relapsed/refractory follicular lymphoma; results posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Follicular Lymphoma

Drugs mentioned

• Bendamustine (Bendamustine)
• Rituximab (rituximab)
• Venetoclax (venetoclax)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Follicular Lymphoma | Phase 2 | Status: COMPLETED | Results posted: 2017-10-13